Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Adenoviral Delivery of Signaling Pathway Sensors into Target Cells, GE Healthcare
December 2005
SHARING OPTIONS:

GE Healthcare launched Ad-A-Gene Vectors, a large range of ready-to-use, validated adenoviral vector gene delivery reagents. The reagents expand the possibilities for lead compound profiling, drug target validation and basic research by enabling the rapid development of transient cell signaling assays. The system can greatly aid secondary screening and early-stage drug discovery by allowing researchers to study cell signaling effectively in a wide variety of cell types including those that are physiologically relevant to disease states. The Ad-A-Gene Vectors save time by providing ready-to-use reagents for simple and efficient delivery of signaling pathway sensors into mammalian cells via viral transduction.
 
Researchers simply add the Ad-A-Gene Vector to the cell culture and within 24 hours, cells will be expressing the transgene ready for assay development. Moreover, the system reduces error and provides reproducible results because each Ad-A-Gene Vector batch is functionally validated and tested. Among the advantages of adenoviral vectors, the Ad-A-Gene Vector DNA does not integrate into the host cell genome, therefore, the expression and functional activity of the sensor is not affected by an integration event.
 
GE Healthcare
800.526.3593

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.